Search

Your search keyword '"Rottenstreich, Misgav"' showing total 675 results
Start Over Author "Rottenstreich, Misgav"
Sorry, I don't understand your search. ×
675 results on '"Rottenstreich, Misgav"'

80. Management of Pregnancy in Women of Advanced Maternal Age: Improving Outcomes for Mother and Baby [Corrigendum]

Author

Glick,Itamar, Kadish,Ela, Rottenstreich,Misgav, Glick,Itamar, Kadish,Ela, and Rottenstreich,Misgav

Abstract

Glick I, Kadish E, Rottenstreich M. Int J Womens Health. 2021;13:751-759. Page 756, Autism Spectrum Disorder section, second paragraph, first sentence, the text “A large meta-analysis, including 16 epidemiological papers with 5687 autism spectrum disorder (ASD) cases and 8,655,576 control subjects, was conducted” should read “A large meta-analysis, including 16 epidemiological papers with 25,687 autism spectrum disorder (ASD) cases and 8,655,576 control subjects, was conducted”. The authors apologize for this error.

Published
2023

82. Covid-19 third vaccination during pregnancy: maternal and neonatal outcomes—a retrospective study.

Author

Rottenstreich, Misgav, Rotem, Reut, Wiener-Well, Yonit, Grisaru-Granovsky, Sorina, and Sela, Hen Y.

Subjects
*COVID-19 vaccines, *BOOSTER vaccines, *COVID-19, *VACCINATION status, *COVID-19 pandemic
Abstract

Purpose: To evaluate the impact of Covid-19 (Pfizer-BioNTech BNT162b2) third booster dose vaccination during pregnancy on maternal and neonatal outcomes. Methods: This is a multicenter, retrospective computerized database study. Parturients who delivered in Israel between August and December 2021 with full records of Covid-19 disease and vaccination status were included. Those who received third booster during pregnancy were compared to those who received two doses of vaccine during pregnancy and to unvaccinated parturients. Various adverse maternal and neonatal outcomes were evaluated. Parturients who were previously positive with Covid-19 PCR swabs during pregnancy or before pregnancy were excluded. Univariate analysis was followed by multivariate analysis. Results: A total of 2583 women were included in the analysis; 626 received the third booster dose of the BNT162b2 Covid-19 vaccine, 1094 received two doses of the vaccine, and 863 unvaccinated women. Maternal and neonatal outcomes were comparable between the study groups. An adjusted multivariable logistic regression analysis demonstrated that receiving the third booster was not associated with an increase in neither composite adverse maternal or neonatal outcome (aOR 0.9; 95% CI [0.65–1.22], p = 0.47; aOR 0.7; 95% CI [0.53–1.035], p= 0.09, respectively) when compared to those who received two doses of the vaccine. However, administration of the third booster dose during pregnancy was associated with a reduced composite adverse neonatal outcome when compared to unvaccinated women (aOR 0.6; 95% CI [0.42–0.86], p = 0.01). Conclusion: Receiving the third booster dose of the BNT162b2 Covid-19 vaccine during pregnancy is not associated with an increased risk of any adverse maternal outcomes and may be beneficial for the neonates. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results